Last updated on July 2019

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis


Brief description of study

Phase 1B randomized, double-blind, placebo-controlled, two-cohort clinical trial of ABI-M201 in adult subjects with mildly-to-moderately active Ulcerative Colitis(UC) and ongoing treatment with mesalamine.

Detailed Study Description

This multi-center randomized, double-blind, placebo-controlled study will evaluate the safety of ABI-M201 and its effects on disease activity measures in men and women with mildly-to-moderately active UC and ongoing treatment with mesalamine. The study will consist of 2 sequential, non-overlapping participant cohorts, separated by intervening interim analysis (IA). Both cohorts will involve 8-weeks of study drug treatment. Interim data from the initial treatment cohort (Cohort A) will inform decision to advance to the subsequent second cohort (Cohort B) and its dose selection. 20 subjects will be randomized to cohort A (1:1 allocation) and receive treatment with 1 capsule per day of ABI-M201 versus Placebo. 24 subjects will be randomized to cohort B (3:1 allocation) and receive treatment with 1-5 capsules per day of ABI-M201 versus Placebo.

Clinical Study Identifier: NCT03923478

Find a site near you

Start Over

(Investigator Site)

San Carlos, CA United States
  Connect »

(Investigator Site)

Decatur, GA United States
  Connect »

(Investigator Site)

Shreveport, LA United States
  Connect »

(Investigator Site)

Chesterfield, MI United States
  Connect »

(Investigator Site)

Houston, TX United States
  Connect »

(Investigator Site)

Rockville, MD United States
  Connect »

(Investigator Site)

Rochester, MN United States
  Connect »

(Investigator Site)

Jackson, TN United States
  Connect »

(Investigator Site)

Ogden, UT United States
  Connect »

(Investigator Site)

Bellevue, WA United States
  Connect »

(Investigator Site)

Milwaukee, WI United States
  Connect »